Articles tagged with Cancer Immunotherapy
Researchers discovered noncoding cryptic peptides as an alternative source of target antigens for ovarian cancer. The findings could improve treatment approaches by mobilizing the immune system to attack tumor cells.
A pilot study shows that a text messaging system can safely reduce the amount of time some patients spend receiving cancer treatment. The platform, which was tested in a clinical trial, allowed patients to complete symptom checks and receive approval for fast-tracking their treatments, saving them over an hour per visit.
Researchers at UCSF have identified unique, cancer-specific proteins created through mistakes in RNA splicing. These antigens could be used to create potent immunotherapies that recognize and attack hard-to-treat tumors. The discovery offers new hope for glioma patients and expands the number of targets available for cancer therapy.
A self-assembling nanoplatform, M@P, has been designed to target tumor cells and induce immunogenic cell death through pyroptosis and ferroptosis. The nanoplatform promotes a robust systemic antitumor immune response by producing tumor-specific antigens and maturing dendritic cells.
Researchers found that Black women with triple-negative breast cancer are less likely to receive immunotherapy treatment, even when accounting for socioeconomic factors. The study analyzed data from over 10,000 patients and found a significant disparity in immunotherapy response between racial groups.
Researchers have developed a 'gut-on-chip' model that replicates intestinal inflammation and predicts response to immunotherapy in melanoma patients. The device differentiates between major intestinal populations and reproduces realistic environments.
The Damon Runyon-St. Jude Pediatric Cancer Research Fellowship aims to address a funding gap for pediatric cancer research. The program supports innovative projects that could significantly impact the diagnosis or treatment of one or more pediatric cancers.
The Colorectal Cancer Alliance has awarded new grants to researchers, convened top scientists at the Cure CRC Summit, and launched K-SPY, a groundbreaking multi-center platform trial for high-risk colorectal cancer cases. The initiative aims to improve outcomes for millions affected by the disease.
Researchers identified vitamin E succinate as an effective agent controlling tumor growth by promoting FTO degradation. The compound enhances T-cell mediated cytotoxicity through tumor-intrinsic FTO suppression, showing potential as a therapeutic strategy for cancers resistant to immunotherapy.
Researchers at Dana-Farber Cancer Institute present studies on novel treatments for prostate, kidney, and bladder cancers. The team introduces a novel HIF-2α inhibitor called casdatifan, which shows promising early clinical activity in heavily pretreated patients with clear cell renal cell carcinoma.
Researchers have created an immune map for pancreatic cancer, showing why some tumours are more susceptible to macrophage-based therapies. The study identifies potential avenues for improved treatment approaches, including boosting certain cell responses and depleting suppressive immune cells.
A novel mechanism has been discovered whereby a short form of IL-18 generated by caspase-3 cleavage in tumor cells activates natural killer cells to suppress tumor growth, offering new therapeutic opportunities. NK cells play a crucial role in cancer immunotherapy due to their rapid response and broad anti-tumor activity.
A new study reveals that microglia can be reprogrammed from a tumor-promoting state to one that strengthens antitumor responses, reducing brain metastases growth and enhancing immunotherapy responses. Researchers identified a key signaling pathway that, when blocked, reverses the protumoral function of microglia.
Researchers at the University of Melbourne have identified a rare type of immune cell, called stem-like T cells, that holds the key to maintaining powerful, long-term immune responses. ID3+ T cells have the remarkable ability to resist burnout and maintain a powerful immune response over time.
Researchers at Memorial Sloan Kettering Cancer Center have made a breakthrough in creating allogeneic CAR T cells that can persist in fighting cancer without being rejected by patients. By modifying donor cells with the HIV protein Nef, the cells can survive and remain potent in treating various types of cancer.
Researchers at the University of Pittsburgh have developed a new way to grow T cells that can live longer and better destroy cancer cells in mice. By adding a compound called dichloroacetate to growth media, they created T cells less reliant on glucose and more efficient at using other energy sources.
Researchers have identified a unique population of T cells that play a critical role in successful treatment of relapsed acute myeloid leukemia. A healthier immune environment in the bone marrow supports these cells and their cancer-fighting abilities.
A new combination therapy combining systemic interferon-I with local imiquimod application showed promising results in treating melanoma and breast cancer. The therapy activated the adaptive immune system to fight distant metastases, reducing tumor relapses and increasing sensitivity to checkpoint inhibitors.
A new study published in Oncotarget discovered an anti-correlation between PD-1 and KLRG1 expression in human tumor infiltrating CD8 T cells. This finding suggests the potential for combination therapy to enhance cancer treatment by targeting both markers simultaneously, which could lead to more significant and long-lasting benefits.
A new study published in Cell reveals significant differences in the immune response of children and adults to cancer, with potential implications for targeted therapies. The research shows that children's tumours are generally less inflammatory and have fewer mutations, making them appear less foreign to their immune system.
Researchers have discovered that a protein called CD74 can predict which people with bowel cancer may respond best to immunotherapy. This finding could lead to the development of a test to identify eligible patients and widen access to this treatment, benefiting hundreds of previously ineligible individuals.
A research team at Memorial Sloan Kettering Cancer Center has identified a novel molecular pathway leading to the formation of tertiary lymphoid structures (TLSs) in tumors. TLSs are immune cell clusters that can boost the local immune response and may be harnessed for immunotherapy treatments.
A new type of cell-based immunotherapy has been shown to be safe and effective in treating B-cell lymphomas, with early data suggesting it could offer a less toxic alternative to CAR-T cell therapies. The approach uses off-the-shelf CAR-natural killer cells that can target cancer cells in two different ways.
Scientists at Salk Institute discovered that removing bile acid-creating protein BAAT and adding bile acid UDCA controls tumor growth in mice with liver cancer. UDCA supplements may be a quick solution to improving liver cancer patient outcomes.
Researchers discovered that DNA repair determines how cancer cells die following radiotherapy, with specific pathways triggering cell death noticed by the immune system. Blocking these pathways can force cancer cells to die in a manner that alerts the immune system, leading to new potential treatments.
A new study has identified macrophage activity as a key predictor of which skin cancer patients are most likely to respond to immunotherapy. The findings aim to improve personalized medicine for cancer patients and enable clinicians to select effective treatments, reducing side effects and costs.
A new study by Mass General Brigham researchers reveals that a novel immunotherapy can eliminate precancerous spots and prevent skin cancer through the activation of specific immune cells. The therapy successfully cleared over 95% of facial lesions and showed long-term efficacy, with benefits lasting up to five years after treatment.
ISM1745, a potentially best-in-class small molecule inhibitor, has been nominated as a preclinical candidate for the treatment of MTAP-deleted cancers. It targets Protein arginine methyltransferase 5 (PRMT5), which is elevated in various cancers and correlates with poor prognostic outcomes.
Scientists at Goethe University Frankfurt have discovered a new way to tailor natural killer cells to target leukemia cells, improving their efficacy. The researchers used CRISPR/Cas9 gene editing to disable an immune checkpoint, allowing the modified cells to attack cancer cells more effectively.
Researchers identified YTHDF2 as a key player in advancing blood cancers, which can help cancer cells evade immune system detection. A new compound CCI-38 targets and suppresses YTHDF2, reducing aggressive blood cancer growth.
Researchers analyzed individual cells from two craniopharyngioma subtypes to identify specific cell types, their features, and interactions. The study found distinct cell types linked to tumor development and immune response in both adamantinomatous and papillary craniopharyngiomas.
Researchers at Salk Institute establish a novel framework for the relationship between nutrition and cell identity. They found that a nutritional switch from acetate to citrate plays a key role in determining T cell fates, shifting them from active effector cells to exhausted cells.
The PROSPECT-Lung trial evaluates the role of immunotherapy before and after surgery in resectable non-small cell lung cancer patients. The trial aims to determine whether adding immune checkpoint inhibitors to standard chemotherapy improves survival outcomes.
Researchers developed an immunotherapeutic platform using lipid-based nanoparticles to deliver therapeutic mRNAs, showing improved efficacy and reduced toxicity. The therapy stimulates the immune system to recognize and eliminate cancer cells, while preserving beneficial immune responses.
Dr. Christopher Seet has received a $2.9 million R37 MERIT Award from the National Cancer Institute to develop innovative T cell therapies for cancer. The grant will support research into iPSC-derived T cells, which can be engineered for enhanced tumor-fighting capabilities.
A phase 3 study demonstrated nearly 75% complete cancer remission in patients with high-risk bladder cancer unresponsive to BCG therapy. The novel treatment, cretostimogene grenadenorepvec, was well-tolerated and did not require bladder removal surgery.
A groundbreaking phase one clinical trial explores a novel cell-based immunotherapy for breast cancer, demonstrating significant shrinkage of tumors and minimal side effects. The treatment leverages dendritic cells to trigger an organized immune system attack on cancer, offering hope for replacing or reducing the need for chemotherapy.
Mesenchymal stem cells (MSCs) show promise in delivering treatments directly to cancer cells and boosting the immune system's fight against cancer. However, ongoing research highlights challenges related to MSC behavior, including variability in their effects and potential to create conditions that support tumor growth.
Researchers have identified UBA1 enzyme as key mediator for immune response to tumors, inhibiting its activity increases T-cell recruitment and lowers tumor resistance. Pairing UBA1 inhibitors with immune checkpoint blockade therapies may make immunotherapy more effective for patients with 'cold' tumors.
Researchers at the Wistar Institute have designed a novel trispecific antibody that targets glioblastoma antigens, providing long-term survival and sustained antitumor efficacy in heterogeneous GBM challenge models. The treatment promotes antitumor cytotoxicity with patient immune cells.
The ESMO Immuno-Oncology Congress 2024 will present key findings on new therapeutic opportunities and management of treatment-related toxicities. Leading experts will share their research advancements in the rapidly evolving field of immuno-oncology.
A large-scale analysis found that cancer immunotherapies are equally effective for both Black and white patients, with Black patients experiencing a lower risk of severe side effects. The study looked at data from over 26,000 patients treated with immune checkpoint inhibitors through the Veteran Health Administration.
Researchers at WashU Medicine engineered a probiotic that delivers immunotherapy directly to the gut, shrinking tumors in mice. The probiotic uses a yeast-based system to produce immune checkpoint inhibitors, potentially treating hard-to-reach cancers.
DZ-002 delivers anticancer drugs exclusively to cancer cells using a cancer-targeting dye carrier, improving tumor diagnosis, detection, and treatment. The technology aims to enhance patient survival rates and quality of life.
A phase II clinical trial showed that combining radiation, chemotherapy, and immunotherapy can shrink tumors and allow surgery, resulting in significantly improved outcomes. The study found that patients who underwent surgery had a 82% reduction in risk of death at one year follow-up.
Researchers create a simple and innovative test that enables real-time monitoring of modified T cells in patients with cancer. The test, which requires only a small blood sample, helps clinicians track the function of these cancer-fighting cells over time.
Researchers have developed a simple and innovative test to monitor the function of cancer-fighting T cells over time. The plug-and-play approach requires only a small blood sample and can be adapted for use in various viral infections and cancer therapies.
New treatment combinations and predictive biomarkers hold promise for improving bladder cancer outcomes. The NIAGARA trial showed that combining immune checkpoint inhibitors with chemotherapy can significantly increase two-year survival rates and reduce cancer recurrences.
A new clinical trial found that the addition of immunotherapy drug pembrolizumab to standard treatment improved disease-free survival rates for patients with stage 3 soft tissue sarcoma. The study showed that pembrolizumab reduced recurrence or death for patients by 15 percentage points compared to standard treatment.
Researchers developed a single-cell RNA-sequencing atlas of the Multiple Myeloma immune microenvironment across disease stages. The atlas reveals potential resistance mechanisms and identifies conventional dendritic cells as a targetable population in MM.
The review explores the impact of extracellular matrix (ECM) geometry on immune cell behavior and treatment efficacy. Specific ECM configurations, known as Tumor-Associated Collagen Signatures (TACS), create physical barriers that limit immune cell access to tumors.
A study by Niigata University found that AI analysis of PET/CT images can predict the occurrence of interstitial lung disease, a serious side effect of immunotherapy. Patients with high inflammation in non-cancerous lungs are at a higher risk of developing this condition.
Researchers at POSTECH have identified GLUT3 as essential for the suppressive function of regulatory T cells in tumor microenvironments, which can be targeted for cancer immunotherapy. The team's findings highlight the critical role of GLUT3 in regulating protein modifications that sustain immune suppression within tumors.
Researchers at UCLA Health Jonsson Comprehensive Cancer Center have shown that combining pembrolizumab, an immunotherapy drug, with standard chemotherapy can improve treatment outcomes for patients with advanced small cell bladder cancer and small cell/neuroendocrine prostate cancer. The study found that the combination treatment resul...
Researchers have developed an immunotherapy that targets glioblastoma by turning its microenvironment against it. The treatment uses CAR T-cells with a blueprint for a molecule that blocks tumor signals, allowing macrophages and microglia to support the attack on cancer cells.
Researchers at MD Anderson Cancer Center present promising new treatments, including a gastric cancer therapy using T cell antigen coupler technology. Additionally, COVID-19 mRNA vaccines are shown to improve responses to immune checkpoint inhibitors in patients with non-small cell lung and melanoma cancers.
Researchers at Cleveland Clinic have made significant progress in their novel vaccine aimed at preventing triple-negative breast cancer. The study found that the investigational vaccine was generally well-tolerated and produced an immune response in most patients, with the highest tolerated dose to date identified.
Researchers have found that combining the VIGex gene expression signature with liquid biopsy analysis improves response prediction to immunotherapy in patients with advanced solid tumors. The study analyzed tumor samples and circulating tumor DNA (ctDNA) by liquid biopsy, showing that the VIGex-Hot subgroup was associated with higher o...
Researchers at Michigan Medicine found that SLC13A3 transporter impairs tumor immunity by endowing ferroptosis resistance. This discovery suggests a potential target for improving immunotherapy responses in cancer patients.
Researchers document remarkable response to pembrolizumab in patient with metastatic adenosquamous pancreatic cancer (ASCP) and KRAS G12C mutation. The study highlights potential shift in treatment of ASCP, a rare form of pancreatic cancer traditionally underserved by current therapies.